Get the Stockscreener App
21.12
1.29%
0.27
After Hours:
21.43
0.31
+1.47%
Summit Therapeutics Inc stock is traded at $21.12, with a volume of 3.54M.
It is up +1.29% in the last 24 hours and up +31.02% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$20.85
Open:
$21.5
24h Volume:
3.54M
Relative Volume:
1.32
Market Cap:
$16.38B
Revenue:
$220.00K
Net Income/Loss:
$-1.08B
P/E Ratio:
-14.62
EPS:
-1.4448
Net Cash Flow:
$-326.53M
1W Performance:
+12.28%
1M Performance:
+31.02%
6M Performance:
-6.71%
1Y Performance:
-14.22%
1-Day Range:
$21.03
$22.18
1-Week Range:
$18.86
$22.18
52-Week Range:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
21.12 | 16.17B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic - MSN
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - Stock Traders Daily
Summit Therapeutics has scarcity value in a crowded drug race: Analyst - MSN
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - ADVFN
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Aug PostEarnings: Can Summit Therapeutics Inc be the next market leader2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
Inflation Data: Can Summit Therapeutics Inc stock outperform in a bear marketBreakout Watch & Stock Portfolio Risk Control - baoquankhu1.vn
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026 - Meyka
Stifel initiates coverage of Summit Therapeutics (SMMT) with buy recommendation - MSN
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Sahm
SMMT Upgraded to Buy by Citigroup on April 08, 2026 - Meyka
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
SMMT : POTENTIAL BOUNCEBACK Click Through The Up Coming Page (2dUA4zfHbg) - Mshale
SUMMIT THERAPEUTICS INC BIG TRADING SWING | SMMT STOCK Simply Click The Next Internet Page (JHLdCFn8fQ) - Mshale
Citigroup starts coverage of Summit Therapeutics Inc (SMMT), Apr 08 2026, Buy - Meyka
What's Going On With Summit Therapeutics Stock Wednesday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
$Summit Therapeutics (SMMT.US)$ - Moomoo
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Bu - GuruFocus
Pullback Watch: Is Summit Therapeutics Inc forming higher highs and higher lowsQuarterly Portfolio Review & Low Drawdown Investment Ideas - baoquankhu1.vn
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Buy' Rating | SMMT Stock News - GuruFocus
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aug Selloffs: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Market Review & High Accuracy Swing Trade Signals - baoquankhu1.vn
Stifel Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $45 - Moomoo
Sentiment Recap: Does Summit Therapeutics Inc have a sustainable dividendInsider Buying & Expert Curated Trade Ideas - baoquankhu1.vn
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - MSN
Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) asks shareholders to approve 8M-share Plan increase - Stock Titan
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN
Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo
Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com
(SMMT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Summit plunges 80 percent after muscle-wasting disorder drug fails - AOL.com
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - MSN
Barclays Remains a Hold on Summit Therapeutics (SMMT) - The Globe and Mail
Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo
Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm
Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - finance.yahoo.com
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):